Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)
Go back to Novavax Reports Fourth-Quarter and Year-End 2013 Financial Results and Initiation of Phase 1/2 Clinical Trial of Its H7N9 Avian Influenza VLP Vaccine Candidate With Matrix-M(TM)| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.00 +0.65 (6.95%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $9.35 | 52 Week High | $9.23 | |||
| Open | $9.61 | 52 Week Low | $1.16 | |||
| Day High | $10.38 | P/E | N/A | |||
| Day Low | $9.61 | EPS | $-0.30 | |||
| Volume | 8,876,153 | |||||
